Robert Roskoski

20.9k total citations · 14 hit papers
173 papers, 16.3k citations indexed

About

Robert Roskoski is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Robert Roskoski has authored 173 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Molecular Biology, 33 papers in Oncology and 21 papers in Cellular and Molecular Neuroscience. Recurrent topics in Robert Roskoski's work include PI3K/AKT/mTOR signaling in cancer (20 papers), Protein Kinase Regulation and GTPase Signaling (19 papers) and Biochemical and Molecular Research (16 papers). Robert Roskoski is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (20 papers), Protein Kinase Regulation and GTPase Signaling (19 papers) and Biochemical and Molecular Research (16 papers). Robert Roskoski collaborates with scholars based in United States, Italy and Germany. Robert Roskoski's co-authors include Kent E. Vrana, Fabian Hartl, Fritz Lipmann, Horst Kleinkauf, Paul Cook, Deepak Bhatnagar, Wieland Gevers, Phillip G. Schmid, Abdollah Sadeghi‐Nejad and Alan H. Stokes and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Robert Roskoski

167 papers receiving 14.8k citations

Hit Papers

ERK1/2 MAP kinases: Structu... 1983 2026 1997 2011 2012 2013 1983 2015 2015 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ERK1/2 MAP kinases: Structure, function, and regulation
    2012 1.2k citations Robert Roskoski Pharmacological Research profile →
  2. The ErbB/HER family of protein-tyrosine kinases and cancer
    2013 1.0k citations Robert Roskoski Pharmacological Research profile →
  3. [1] Assays of protein kinase
    1983 797 citations Robert Roskoski profile →
  4. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
    2015 620 citations Robert Roskoski Pharmacological Research profile →
  5. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
    2015 455 citations Robert Roskoski Pharmacological Research profile →
  6. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
    2019 424 citations Robert Roskoski Pharmacological Research profile →
  7. Properties of FDA-approved small molecule protein kinase inhibitors
    2019 400 citations Robert Roskoski Pharmacological Research profile →
  8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
    2018 363 citations Robert Roskoski Pharmacological Research profile →
  9. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
    2018 303 citations Robert Roskoski Pharmacological Research profile →
  10. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
    2021 269 citations Robert Roskoski Pharmacological Research profile →
  11. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
    2022 196 citations Robert Roskoski Pharmacological Research profile →
  12. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
    2024 185 citations Robert Roskoski Pharmacological Research profile →
  13. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update
    2021 168 citations Robert Roskoski Pharmacological Research profile →
  14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update
    2025 15 citations Robert Roskoski Pharmacological Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Roskoski United States 57 9.9k 4.1k 2.1k 1.6k 1.4k 173 16.3k
Doriano Fabbro Switzerland 74 12.4k 1.3× 3.7k 0.9× 1.5k 0.7× 1.8k 1.1× 1.4k 1.0× 223 20.3k
Alexander Levitzki Israel 74 14.3k 1.4× 5.9k 1.4× 1.5k 0.7× 1.7k 1.1× 1.8k 1.3× 328 22.3k
Stanley T. Crooke United States 83 17.8k 1.8× 4.0k 1.0× 1.1k 0.5× 2.3k 1.4× 2.4k 1.7× 415 25.7k
Paul A. Marks United States 72 17.9k 1.8× 4.6k 1.1× 935 0.4× 1.4k 0.9× 1.0k 0.7× 202 22.6k
Steven Grant United States 79 16.7k 1.7× 6.3k 1.5× 1.3k 0.6× 1.2k 0.7× 2.3k 1.6× 451 23.2k
Harvey R. Herschman United States 81 12.5k 1.3× 3.7k 0.9× 907 0.4× 912 0.6× 2.7k 1.9× 330 25.2k
Thomas G. Cotter Ireland 64 11.8k 1.2× 2.6k 0.6× 808 0.4× 804 0.5× 1.8k 1.3× 244 18.4k
Saı̈d M. Sebti United States 73 11.0k 1.1× 6.7k 1.7× 881 0.4× 1.8k 1.1× 2.0k 1.4× 250 16.7k
Paul Dent United States 81 15.6k 1.6× 7.0k 1.7× 1.8k 0.8× 753 0.5× 2.4k 1.7× 388 23.1k
Victoria M. Richon United States 68 20.3k 2.1× 5.2k 1.3× 967 0.5× 1.3k 0.8× 1.4k 1.0× 123 23.0k

Countries citing papers authored by Robert Roskoski

Since Specialization
Citations

This map shows the geographic impact of Robert Roskoski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Roskoski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Roskoski more than expected).

Fields of papers citing papers by Robert Roskoski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Roskoski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Roskoski. The network helps show where Robert Roskoski may publish in the future.

Co-authorship network of co-authors of Robert Roskoski

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Roskoski. A scholar is included among the top collaborators of Robert Roskoski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Roskoski. Robert Roskoski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roskoski, Robert. (2026). Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update. Pharmacological Research. 224. 108107–108107.
2.
Roskoski, Robert. (2025). Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update. Pharmacological Research. 217. 107805–107805. 4 indexed citations
3.
Roskoski, Robert. (2025). Vascular endothelial cells and angiogenesis. Pharmacological Research. 221. 107983–107983.
4.
Roskoski, Robert. (2025). Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. Pharmacological Research. 222. 108058–108058.
5.
Roskoski, Robert. (2025). Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update. Pharmacological Research. 216. 107723–107723. 15 indexed citations breakdown →
6.
Roskoski, Robert. (2023). Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. Pharmacological Research. 194. 106847–106847. 17 indexed citations
7.
Roskoski, Robert. (2023). Futibatinib (Lytgobi) for cholangiocarcinoma. Trends in Pharmacological Sciences. 44(3). 190–191. 12 indexed citations
8.
Roskoski, Robert. (2021). Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological Research. 168. 105579–105579. 50 indexed citations
9.
Eyck, Patrick Ten, et al.. (2020). NIH funding trends to US medical schools from 2009 to 2018. PLoS ONE. 15(6). e0233367–e0233367. 17 indexed citations
10.
Roskoski, Robert. (2019). Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacological Research. 152. 104609–104609. 424 indexed citations breakdown →
11.
Roskoski, Robert. (2017). ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacological Research. 121. 202–212. 109 indexed citations
12.
Roskoski, Robert. (2016). Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacological Research. 117. 20–31. 86 indexed citations
13.
Roskoski, Robert. (2015). Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological Research. 103. 26–48. 620 indexed citations breakdown →
14.
Roskoski, Robert. (2014). ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacological Research. 87. 42–59. 175 indexed citations
15.
Roskoski, Robert. (2007). Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochemical and Biophysical Research Communications. 356(2). 323–328. 345 indexed citations
16.
Roskoski, Robert. (2004). The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and Biophysical Research Communications. 319(1). 1–11. 309 indexed citations
17.
Roskoski, Robert. (2004). Src protein–tyrosine kinase structure and regulation. Biochemical and Biophysical Research Communications. 324(4). 1155–1164. 456 indexed citations
18.
Stokes, Alan H., et al.. (1998). Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. Journal of Neuroscience Research. 54(5). 691–697. 144 indexed citations
19.
Roskoski, Robert, et al.. (1991). Tyrosine Hydroxylase Purification from Rat PC 12 Cells. Protein Expression and Purification. 2(1). 10–14. 10 indexed citations
20.
Bhatnagar, Deepak, et al.. (1988). Differential sensitivity of neural and non-neural protein kinase isozymes to cyclic AMP. Biochemical and Biophysical Research Communications. 156(2). 801–806. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Doriano Fabbro Breakdown of academic impact, for papers by Alexander Levitzki Breakdown of academic impact, for papers by Stanley T. Crooke Breakdown of academic impact, for papers by Paul A. Marks Breakdown of academic impact, for papers by Steven Grant Breakdown of academic impact, for papers by Harvey R. Herschman Breakdown of academic impact, for papers by Thomas G. Cotter Breakdown of academic impact, for papers by Saı̈d M. Sebti Breakdown of academic impact, for papers by Paul Dent Breakdown of academic impact, for papers by Victoria M. Richon
Rankless by CCL
2026